Cite
Abstract 2163: Circulating H3K27 nucleosomes to monitor lung cancer patients during treatment, a universal biomarker quantifying the molecular residual disease (MRD) in plasma samples
MLA
Emmanuel Grolleau, et al. “Abstract 2163: Circulating H3K27 Nucleosomes to Monitor Lung Cancer Patients during Treatment, a Universal Biomarker Quantifying the Molecular Residual Disease (MRD) in Plasma Samples.” Cancer Research, vol. 83, Apr. 2023, p. 2163. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........d59e549eb704d2358eb0d13ed6b5712f&authtype=sso&custid=ns315887.
APA
Emmanuel Grolleau, Julie Candiracci, Arnaud Gauthier, Gaelle Lescuyer, David Barthelemy, Christine Haon, Florence Geiguer, Margaux Raffin, Nathalie Hardat, Julie Balandier, Rémi Rabeuf, Anne-Sophie Wozny, Guillaume Rommelaere, Claire Rodriguez-Lafrasse, Fabien Subtil, Sébastien Couraud, Marielle Herzog, & Lea Payen-Gay. (2023). Abstract 2163: Circulating H3K27 nucleosomes to monitor lung cancer patients during treatment, a universal biomarker quantifying the molecular residual disease (MRD) in plasma samples. Cancer Research, 83, 2163.
Chicago
Emmanuel Grolleau, Julie Candiracci, Arnaud Gauthier, Gaelle Lescuyer, David Barthelemy, Christine Haon, Florence Geiguer, et al. 2023. “Abstract 2163: Circulating H3K27 Nucleosomes to Monitor Lung Cancer Patients during Treatment, a Universal Biomarker Quantifying the Molecular Residual Disease (MRD) in Plasma Samples.” Cancer Research 83 (April): 2163. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........d59e549eb704d2358eb0d13ed6b5712f&authtype=sso&custid=ns315887.